DEBIO 1347 In Patients With GastroIntestinal Cancers Harboring An FGFR Gene Fusion: Preliminary Results

Presented at ESMO GI 2019, Barcelona, Spain

Ignacio Matos¹, Lipika Goyal², James M. Cleary³, Martin H. Voss⁴, Do-Youn Oh⁵, Funda Meric-Bernstam⁶, Matthew CH Ng⁷, Gopa Iyer⁴, Nobuya Ishii⁸, Youyou Hu⁹, Anne Vaslin⁹, Anna Pokorska-Bocci⁹, Valerie Nicolas⁹, Yulia Kirpicheva⁹, Claudio Zanna⁹, Keith Flaherty², Josep Tabernero¹, David Hyman⁴

1. Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain;
2. Massachusetts General Hospital Cancer Center, Boston, MA;
3. Dana-Farber Cancer Institute, Boston, MA;
4. Memorial Sloan-Kettering Cancer Center, New York, NY;
5. Seoul National University Hospital, Seoul, Korea;
6. The University of Texas MD Anderson Cancer Center, Houston, TX;
7. National Cancer Centre Singapore, Singapore;
8. Chugai Pharmaceutical Co., Ltd., Tokyo, Japan;
9. Debiopharm International SA, Lausanne, Switzerland